Alnylam Pharmaceuticals | ALNY - Betriebsaufwand

Aktienkurs
327.25
Täglich Wechseln
7.73 2.42%
Monatlich
1.13%
Jährlich
34.52%
Q2 Prognose
309.25




Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 23M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Tectonic Therapeutic USD 21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xencor USD 81.86M 13.35M 2025-12